The BCR gene and Philadelphia chromosome-positive leukemogenesis

Cancer Research

Volumn 61, Issue 6, 2001, Pages 2343-2355

  Laurent, E ^a   Talpaz, M ^a   Kantarjian, H ^a   Kurzrock, R ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CELL ADHESION MOLECULE; PHOSPHOTRANSFERASE; RAS PROTEIN; STAT5 PROTEIN;

APOPTOSIS; BINDING AFFINITY; BINDING SITE; ENZYME ACTIVATION; EXON; GENE STRUCTURE; GENETIC TRANSCRIPTION; HUMAN; LEUKEMOGENESIS; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR WEIGHT; NONHUMAN; OLIGOMERIZATION; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY MECHANISM; REVIEW; SEQUENCE ANALYSIS; TRANSCRIPTION REGULATION;

ANIMALS; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; ONCOGENE PROTEINS; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCR;

EID: 0035866754     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (257)

1. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
2. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
3. High resolution chromosomes of the t(9;22) positive leukemias
4. Structural organization of the BCR gene and its role in the Ph' translocation
5. An alteration of the human c-Abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity
6. The human cellular ABL gene product in the chronic myelogenous leukemia cell line K562 has an associated tyrosine protein kinase activity
7. Alternative 5′ exons in c-ABL mRNA
8. Bcr-Abl in chronic myelogenous leukemia
9. Expression of c-Abl in Philadelphia-positive acute myelogenous leukemia
10. A novel c-Abl protein product in Philadelphia-positive acute lymphoblastic leukaemia
11. A novel Abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukaemia
12. Unique fusion of BCR and c-ABL genes in Philadelphia chromosome positive acute lymphoblastic leukemia
13. Novel chimaeric protein expressed in Philadelphia positive acute lymphoblastic leukaemia
14. The molecular genetics of Philadelphia chromosome-positive leukemias
15. Fused transcript of ABL and BCR genes in chronic myelogenous leukaemia
16. Evidence of a new chimeric BCR/c-ABL mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome
17. Identification of two normal BCR gene products in the cytoplasm
18. Detection of c-Abl tyrosine kinase activity in vitro permits direct comparison of normal and altered ABL gene products
19. Alternative splicing of RNAs transcribed from the human ABL gene and front the BCR-ABL fused gene
20. An 8-kilobase ABL RNA transcript in chronic myelogenous leukemia
21. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia
22. Molecular analysis of chromosome 22 breakpoints in adult Philadelphia-positive acute lymphoblastic leukaemia
23. The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype
24. New type of BCR/ABL junction in Philadelphia chromosome-positive chronic myelogenous leukemia
25. Evidence that the PHL gene encodes a 160,000-dalton phosphoprotein with associated kinase activity
26. The first BCR gene intron contains breakpoints in Philadelphia chromosome positive leukemia
27. A minute chromosome in human chronic granulocytic leukemia
28. Alternative 5′ end of the BCR-ABL transcript in chronic myelogenous leukemia
29. Identification of a 130Kda BCR related gene product
30. cDNA sequence for human BCR, the gene that translocates to the ABL oncogene in chronic myeloid leukaemia
31. Expression of BCR and BCR-ABL fusion transcripts in normal and leukemic cells
32. Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation
33. Mapping of four distinct BCR-related loci to chromosome region 22q11: Order of BCR loci relative to chronic myelogenous leukemia and acute lymphoblastic leukemia breakpoints
34. ABR, an active BCR-related gene
35. BCR genes and transcripts
36. Analysis of BCR-ABL mRNA in chronic myelogenous leukemia patients and identification of a new BCR-related sequence in human DNA
37. A hypervariable RFLP within the ABR gene
38. The human active breakpoint cluster region-related gene encodes a brain protein with homology to guanine nucleotide exchange proteins and GTPase-activating proteins
39. The 5′ noncoding region of the human leukemia-associated oncogene BCR/ABL is a potent inhibitor of in vitro translation
40. Unique organization of the human BCR gene promoter
41. Characterization of the BCR promoter in Philadelphia chromosome-positive and -negative cell lines
42. The functioning of higher eucaryotic genes
43. Characterization of BCR gene products in hematopoietic cells
44. Rac activity and homology to the DBL nucleotide exchange factor domain
45. Abr and Bcr are multifunctional regulators of the Rho GTP-binding protein family
46. Bcr-Abl and Bcr proteins. Biochemical characterization and localization
47. Multiple BCR-related gene products and their proposed involvement in ligand-induced signal transduction pathways
48. Cell cycle-related shifts in subcellular localization of Bcr: Association with mitotic chromosomes and with heterochromatin
49. Cytoplasmic and nuclear localization of the 130 and 160 kDa Bcr proteins
50. The Bcr-Abl oncoprotein potentially interacts with the xeroderma pigmentosum group B protein
51. Bcr binds to the xeroderma pigmentosum group B protein
52. Transcription factor IIH: A key player in the cellular response to DNA damage
53. The BCR gene encodes a novel serine/threonine kinase activity within a single exon
54. Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family
55. Bcr and Raf form a complex in vivo via 14-3-3 proteins
56. A coiled-coil oligomerization domain of Bcr is essential for the transforming function of Bcr-Abl oncoproteins
57. Bcr-Abl positive 32D myeloid leukemia cells
58. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the Grb-2 adaptor protein
59. Bcr sequences essential for transformation by the BCR-ABL oncogene bind to the Abl SH2 regulatory domain in a nonphosphotyrosine-dependent manner
60. A limited set of SH2 domains binds Bcr through a high-affinity phosphotyrosine-independent interaction
61. A novel transcriptional suppressor located within a downstream intron of the BCR gene
62. A region of proto-dbl essential for its transforming activity shows sequence similarity to a yeast cell cycle gene CDC24, and the human breakpoint cluster gene, BCR
63. The hematopoietically expressed VAV proto-oncogene shares homology with the DBL GDP-GTP exchange factor, the BCR gene, and a yeast gene (CDC24) involved in cytoskeletal organization
64. Rac
65. Increased neutrophil respiratory burst in BCR-null mutants
66. Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho
67. Catalysis of guanine nucleotide exchange on the Cdc42Hs protein by the DBL oncogene product
68. BCR first exon sequences specifically activate the BCR/ABL tyrosine kinase oncogene of Philadelphia chromosome-positive human leukemias
69. Activation of tyrosine kinase and microfilament-binding functions of c-Abl by Bcr sequences in Bcr/Abl fusion proteins
70. The involvement of Bcr in leukemias with the Philadelphia chromosome
71. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates p160 Bcr on tyrosine predominantly within the first Bcr exon
72. Gag-Fps
73. SH2 and SH3 domains: Elements that control interactions of cytoplasmic signaling proteins
74. Proteins with SH2 domains: Transducers in the tyrosine kinase signaling pathway
75. Baculovirus expression of functional p210 BCR-ABL oncogene product
76. p210 Bcr-Abl is complexed to p160 Bcr and Ph-p53 proteins in K562 cells
77. p210 BCR/ABL, p190 BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines
78. The mouse type IV c-ABL gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization
79. Cell cycle-regulated binding of c-Abl tyrosine kinase to DNA
80. Chromosomal localization of human cellular homologues of two vital oncogenes
81. The first intron in the human c-ABL gene is at least 200 kilobases long and is a target for translocations in chronic myelogenous leukemia
82. Normal c-ABL gene protein-a nuclear component
83. Functional role for the c-Abl tyrosine kinase in meiosis I
84. Determination of the human c-Abl consensus DNA binding site
85. The DNA binding domain of the human c-Abl tyrosine kinase preferentially binds to DNA sequences containing an AAC motif and to distorted DNA structures
86. Deletion of an N-terminal regulatory domain of the c-Abl tyrosine kinase activates its oncogenic potential
87. N-terminal mutations activate the leukemogenic potential of the myristylated form of c-Abl
88. An intramolecular SH3-domain interaction regulates c-Abl activity
89. A c-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-Abl tyrosine kinase in the cell cycle
90. p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase
91. Signaling by ABL oncogenes through cyclin D1
92. Interaction between Atm protein and c-Abl in response to DNA damage
93. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation
94. Interaction of c-Abl and p73α and their collaboration to induce apoptosis
95. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage
96. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage
97. Differential phosphorylation of c-Abl in cell cycle determined by Cdc2 kinase and phosphatase activity
98. Identification of Crkl as the constitutively phosphorylated 39-kD tyrosine phosphoprotein in chronic myelogenous leukemia cells
99. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia
100. The nuclear tyrosine kinase c-Abl negatively regulates cell growth
101. Abi-2, a novel SH3-containing protein interacts with the c-Abl tyrosine kinase and modulates c-Abl transforming activity
102. Oncogenic Abl and Src tyrosine kinases elicit the ubiquitin-dependent degradation of target proteins through a Ras-independent pathway
103. Abl-interactor-1, a novel SH3 protein binding to the carboxy-terminal portion of the Abl protein, suppresses v-Abl transforming activity
104. Drosophila Abelson interacting protein (dAbi) is a positive regulator of Abelson tyrosine kinase activity
105. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias
106. Structure/function relationships of Ras and guanosine triphosphatase-activating protein
107. Rho GTPases and signaling networks
108. Isolation of multiple mouse cDNAs with coding homology to Saccharomyces cerevisiae CDC25: Identification of a region related to BCR, VAV, DBL, and CDC24
109. Roles of the CDC24 gene product in cellular morphogenesis during the Saccharomyces cerevisiae cell cycle
110. Budding and cell polarity in Saccharomyces cerevisiae
111. Mutational analysis of CDC42Sc, a Sacchromyces cerevisiae gene that encodes a putative GTP-binding protein involved in the control of cell polarity
112. Molecular characterization of CDC42, a Sacchromyces cerevisiae gene involved in the development of cell polarity
113. Genetic evidence for a functional interaction between Saccharomyces cerevisiae CDC24 and CDC42
114. The cellular functions of small GTP-binding proteins
115. Ras-related proteins
116. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors
117. Characterization of RhoGAP. A GTPase-activating protein for Rho-related small GTPases
118. r protein n-chimaerin, related to both the regulatory domain of protein kinase C and Bcr, the product of the breakpoint cluster region gene
119. 14-3-3 Proteins on the MAP
120. 14-3-3 Protein homologs required for the DNA damage checkpoint in fission yeast
121. Nuclear localization of Cdc25 is regulated by DNA damage a 14-3-3 protein
122. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine
123. Isoforms of 14-3-3 protein can form homo- and heterodimers in vivo and in vitro: Implications for function as adapter proteins
124. Multiparameter studies in lymphoid leukemias
125. Breakpoints on chromosome 9 and 22 in Philadelphia chromosome-positive chronic myelogenous leukemia (CML)
126. CML patients in blast crisis have breakpoints localized to a specific region of the BCR
127. Application of a BCR-specific probe in the classification of human leukaemia
128. Utility of molecular genetic analysis of BCR rearrangement in the diagnosis of chronic myeloid leukemia
129. Philadelphia-positive chronic myeloid leukemia with a chromosome 22 breakpoint outside the breakpoint cluster region
130. 1)-positive leukemias
131. Analysis of breakpoints within the BCR gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia
132. 1-positive ALL
133. Distinguishing the Philadelphia chromosome of acute lymphoblastic leukemia from its counterpart in chronic myelogenous leukemia
134. Heterogeneity of chromosome 22 breakpoint in Philadelphia-positive (Ph+) acute lymphocytic leukemia
135. BCR rearrangement and translocation of the c-ABL oncogene in Philadelphia positive acute lymphoblastic leukemia
136. Establishment and characterization of a cell line, TOM-1, derived from a patient with Philadelphia chromosome-positive acute lymphocytic leukemia
137. A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia
138. Fusion of the BCR and the c-ABL genes in Ph′-positive acute lymphocytic leukemia with no rearrangement in the breakpoint cluster region
139. Variability of the molecular defects corresponding to the presence of a Philadelphia chromosome in human hematologic malignancies
140. Structural alterations of the BCR and ABL genes in Ph1 positive acute leukemias with rearrangements in the BCR gene first intron: Further evidence implicating Alu sequences in the chromosome translocation
141. Frequent and extensive deletion during the 9,22 translocation in CML
142. Bcr-Abl in chronic myelogenous leukemia may correlate with disease progression
143. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
144. Localization of the c-ABL oncogene adjacent to a translocation break point in chronic myelocytic leukaemia
145. Variable breakpoints on the Philadelphia chromosome in chronic myelogenous leukemia
146. Characterization of the translocation breakpoint sequences in Philadelphia-positive acute lymphoblastic leukemia
147. Characterization of genomic BCR-ABL breakpoints in chronic myeloid leukaemia by PCR
148. Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation
149. The BCR gene recombines preferentially with Alu elements in complex BCR-ABL translocations of chronic myeloid leukaemia
150. Detection of major BCR-ABL gene expression at a very low level in blood cells of some healthy individuals
151. The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease
152. Distribution of ABL and BCR genes in cell nuclei of normal and irradiated lymphocytes
153. The nuclear topography of ABL, BCR, PML, and RARα genes: Evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation
154. The juxtaposition of ABL with BCR and risk for fusion may come at a time of BCR replication in late S-phase
155. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 Bcr/Abl fusion protein
156. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR-ABL with c3a2 junction)
157. Relationship between Bcr/Abl fusion proteins and leukemia phenotype
158. A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease?
159. Typical chronic myelogenous leukemia with e19a2 junction BCR/ABL transcript
160. p230 Bcr/Abl protein may be associated with an acute leukaemia phenotype
161. A novel 203 kD aberrant BCR-ABL product in a girl with Philadelphia chromosome positive acute lymphoblastic leukaemia
162. A novel BCR-ABL fusion gene (e6a2) in a patient with Philadelphia chromosome-negative chronic myelogenous leukemia
163. A novel BCR-ABL fusion gene (e2/1a) in a patient with Philadelphia-positive chronic myelogenous leukaemia and an aggressive clinical course
164. Two patients with novel BCR/ABL fusion transcripts (e8/a2 and e13/a2) resulting from translocation breakpoints within BCR exons
165. Expression of p210 and p190 BCR-ABL due to alternative splicing in chronic myelogenous leukaemia
166. Polarized distribution of Bcr-Abl in migrating myeloid cells and co-localization of Bcr-Abl and its target proteins
167. Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines
168. Ras1 activation and binds to Sevenless and Sos protein in vitro
169. Bcr-Abl and Shc and Grb2 adaptor proteins in hematopoietic cells permits growth factor receptor-independent link to Ras activation pathway
170. A 62-kilodalton tyrosine phosphoprotein constitutively present in primary chronic phase chronic myelogenous leukemia enriched lineage negative blast populations
171. Dok. A constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells
172. Identification of the Abl- and RasGAP-associated 62 kDa protein as a docking protein, Dok
173. Bcr-Abl and Bcr-Abl-associated proteins
174. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents
175. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2
176. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death
177. Regulation of the Fas apoptotic cell death pathway by Abl
178. Bcr-Abl exerts its anti-apoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3
179. Bcr-Abl delays apoptosis upstream of procaspase-3 activation
180. A requirement for NF-κB activation in Bcr-Abl-mediated transformation
181. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (Stat) proteins in hematopoietic cell lines transformed by Bcr/Abl
182. c subunit and constitutively induces its tyrosine phosphorylation
183. Bcr/Abl leads to the constitutive activation of Stat proteins, and shares an epitope with tyrosine phosphorylated Stats
184. Bcr/Abl induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members
185. Constitutive activation of Stat5 by the BCR-ABL oncogene in chronic myelogenous leukemia
186. Signal transducer and activator of transcription (Stat)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis
187. Stat5 activation by Bcr-Abl contributes to transformation of K562 leukemia cells
188. Activation of phosphatidylinositol 3-kinase in cells expressing ABL oncogene variants
189. Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells
190. Bcr/Abl to the phosphatidylinositol-3′ kinase pathway
191. Transformation of hematopoietic cells by BCR/ABL requires the activation of a PI-3k/Akt-dependent pathway
192. The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation
193. Bcr-Abl oncoproteins bind directly to activators of the Ras signalling pathway
194. The Bcr-Abl tyrosine kinase inhibits apoptosis by activating a Ras-dependent signaling pathway
195. Integrin-mediated regulation of hematopoiesis: Do Bcr/Abl-induced defects in integrin function underlie the abnormal circulation and proliferation of CML progenitors?
196. Role of abnormal integrin-cytoskeletal interactions in impaired β1 integrin function in chronic myelogenous leukemia hematopoietic progenitors
197. Bcr/Abl directly inhibits expression of Ship, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis
198. Characterization of the translocation breakpoint in a patient with Philadelphia positive, BCR negative acute lymphoblastic leukaemia
199. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products
200. Genetic requirement for Ras in the transformation of fibroblasts and hematopoietic cells by the BCR-ABL oncogene
201. The BCR-ABL oncogene requires both kinase activity and src-homology 2 domain to induce cytokine secretion
202. + leukemia
203. c-Fes
204. Bcr-Abl tyrosine kinase
205. Bcr/Abl
206. Bcr/Abl
207. Bcr/Abl
208. Role of p21 Ras in p210 Bcr-Abl transformation of murine myeloid cells
209. The tetramerization domain-independent Ras activation by Bcr-Abl oncoprotein in hematopoietic cells
210. The 145-kDa protein induced to associate with Shc by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase
211. Ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity
212. Multiple forms of an inositol polyphosphate 5-phosphatase form signaling complexes with Shc and Grb2
213. Purification and molecular cloning of SH2- and SH3-containing inositol polyphosphate-5-phosphatase, which is involved in the signaling pathway of granulocyte-macrophage colony-stimulating factor, erythropoietin, and Bcr-Abl
214. Identification of a second SH2-domain-containing protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP
215. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span
216. A novel SH2-containing phosphatidylinositol 3,4,5-triphosphate 5-phosphatase (Ship2) is constitutively tyrosine phosphorylated and associated with Src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells
217. Fak) by Bcr-Abl oncoprotein
218. Interferon-α restores normal adhesion of chronic myelogenous leukemia hematopoietic progenitors to bone marrow stroma by correcting impaired β1 integrin receptor function
219. Interferon-α restores normal β1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia
220. Inhibition of Bcr-Abl expression with antisense oligodeoxynucleotides restores β1 integrin-mediated adhesion and proliferation inhibition in chronic myelogenous leukemia hematopoietic progenitors
221. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-Bcr/Abl tyrosine kinase activity restores β1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors
222. Adhesion to fibronectin stimulates proliferation of wild-type and BCR/ABL-transfected murine hematopoietic cells
223. BCR/ABL with paxillin in chronic myelogenous leukemia cells
224. Involvement of the adapter protein Crk1 in integrin-mediated adhesion
225. The ABL genes in normal and abnormal cell development
226. Regulation of BCL-2 gene expression by Bcr-Abl is mediated by Ras
227. Constitutive activation of JAKs and Stars in BCR-ABL-expressing cell lines and peripheral blood cells derived from leukemic patients
228. BCR-ABL and constitutively active erythropoietin receptor (cEpoR) activate distinct mechanisms for growth factor-independence and inhibition of apoptosis in Ba/F3 cell line
229. STATs and gene regulation
230. Sequences within the first exon of BCR inhibit the activated tyrosine kinase of c-Abl and the Bcr-Abl oncoprotein
231. Inhibition of Bcr serine kinase by tyrosine phosphorylation
232. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative
233. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
234. r 190,000 Bcr-Abl protein by a tyrosine kinase inhibitor (CGP-57148)
235. Favorable therapeutic index of a p210(Bcr-Abl)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors
236. Selective induction of apoptosis in Philadelphia chromosome-positive chronic myelogenous leukemia cells by an inhibitor of Bcr-Abl tyrosine kinase, CGP 57148
237. L
238. Inhibition of Bcr-Abl induces apoptosis through effects on downstream signaling cascades: Death through abrogation of survival signals
239. Efficacy of an Abl tyrosine kinase inhibitor in conjunction with other antineoplastic agents against BCR-ABL positive cells
240. Altered interferon-α responsiveness in K562 cells pretreated with Abl-tyrosine kinase inhibitor CGP57148B
241. Combination therapy of chronic myelogenous leukemia employing Bcr/Abl specific tyrosine kinase inhibition
242. Clinical efficacy and safety of an Abl specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
243. Activity of an Abl specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis
244. Activity of an Abl specific tyrosine kinase inhibitor in patients with BCR-ABL positive acute leukemias, including chronic myelogenous leukemia in blast crisis
245. A Phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
246. The therapeutic potential of ribozymes
247. Antisense oligonucleotides as therapeutic agents
248. A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo
249. Extremely high and specific activity of DNA enzymes in cells with a Philadelphia chromosome
250. Inhibition of BCR-ABL oncogene expression by novel deoxyribozymes (DNAzymes)
251. In vivo inhibition by a site-specific catalytic RNA subunit of Rnase P designed against the BCR-ABL oncogenic products: A novel approach for cancer treatment
252. Specific BCR-ABL-directed antisense nucleic acids and ribozymes: A tool for the treatment of chronic myelogenous leukemia?
253. Bcr: A negative regulator of the Bcr-Abl oncoprotein
254. Phosphoserine peptides from the serine-rich B box of the Bcr first exon inhibit the Abl and Bcr-Abl kinases
255. RAS and leukemia: From basic mechanisms to gene-directed therapy
256. Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia